Shanghai, China July 4, 2018 – Boehringer Ingelheim, a leading contract manufacturer for biopharmaceutical medicines, has rounded off its full-service capabilities for customers with a new filling line at Shanghai, China. With this latest extension the contract manufacturing business Boehringer Ingelheim BioXcellence™ now offers manufacturing of drug substance, drug product and all corresponding quality control and assurance activities to their customers under one roof at its commercial manufacturing facility OASIS in Shanghai. The new isolator based fill & finish line is in full GMP operations for aseptic filling of liquids in vials.
Editor’s note: this press release originally appeared on Boehringer Ingelheim’s website.
To view the full press release, click here.
News from our Partners
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.